ClinicalTrials.gg
CompletedNCT00297206Updated Sep 11, 2017

A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children

A Phase 1 interventional study of Valaciclovir in Herpes Simplex, sponsored by GlaxoSmithKline. Completed at 13 sites in 3 countries. Open to participants aged 1 Month to 6 Years. Per ClinicalTrials.gov, last updated 2017-09-11.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Jan 2003, registered Feb 2006).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
1 Month to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing valacyclovir in Herpes Simplex — none open to participants now, none under way, none of them phase 3. Valacyclovir · Herpes Simplex.

Enrollment
10th of 21
36 · median 33
Started
2003
with 2 others
Phase 1
6 of 24
none open now
Registered
11th of 24
by date
Lead sponsor
3 of 24
GlaxoSmithKline

Among the 24 studies testing valacyclovir in Herpes Simplex, this one is the 10th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2003, is one of 6 in phase 1, and was the 11th registered.

Herpes Simplex

166 studies on the registry are indexed under Herpes Simplex; 12 are open to participants now.

Browse Herpes Simplex studies →

Open to participants now

None of the 24 studies testing valacyclovir in Herpes Simplex is open now. The open studies under Herpes Simplex, anywhere →

About valacyclovir

Valacyclovir: first FDA approval 1995 (VALTREX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Herpes Simplex studies recruiting now, 4 (40%) set no upper age limit and 1 (10%) stops at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 1 Month to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing valacyclovir in Herpes Simplex as a file.
02

Study summary

Limited data are available on valaciclovir use in children and valaciclovir is not currently approved for use in pediatrics. The marketed formulation of valaciclovir is not ideal for use in pre-adolescent patients who may have trouble swallowing solid oral dosage forms. An extemporaneous suspension formulation of valaciclovir has been developed to expedite the provision of benefits to children similar to those from administration of valaciclovir solid formulations in adults.

03

Conditions studied

  • Herpes Simplex

Browse trials for

Keywords

  • pharmacokinetics herpes varicella herpes labialis Epstein-Barr virus
04

Who can participate

Ages eligible
1 Month to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have a current herpes virus infection.
  • Have neonatally acquired herpes at risk of potential recurrence.
  • or cancer patients at risk for development of a herpes virus infection.

Exclusion criteria

Exclusion criteria:

  • to antiherpetic medications.
  • Impaired hepatic or renal function.
  • Show presence of other serious or unstable underlying disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Subjects in the age group of 2 to less than 6 years will be included

    Drug: Valaciclovir

  • Experimental
    Cohort 2

    Subjects in the age group of 1 to less than 2 years will be included

    Drug: Valaciclovir

  • Experimental
    Cohort 3

    Subjects in the age group of 6 months to less than 1 year will be included

    Drug: Valaciclovir

  • Experimental
    Cohort 4

    Subjects in the age group of 3 months to less than 6 months will be included

    Drug: Valaciclovir

  • Experimental
    Cohort 5

    Subjects in the age group of 1 month to less than 3 months will be included

    Drug: Valaciclovir

Interventions

  • Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.

06

What researchers measure

Primary outcomes

  1. Plasma acyclovir and valaciclovir concentrations pre-dose (within 15 minutes of dose administration) and at 0.5, 1, 2, 4 and 6 hours following administration of the valaciclovir oral suspension dose.

    Time frame: 0.5, 1, 2, 4 and 6 hours

Secondary outcomes

  1. Safety monitoring throughout the study and at the follow up evaluation 2-4 days after the single dose of study medication.

    Time frame: Up to Day 5

07

Study locations

13 sites
  • GSK Investigational Site
    Birmingham, Alabama 35233, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72202, United States
  • GSK Investigational Site
    San Diego, California 92123, United States
  • GSK Investigational Site
    Jacksonville, Florida 32209, United States
  • GSK Investigational Site
    Lexington, Kentucky 40503, United States
  • GSK Investigational Site
    Louisville, Kentucky 40202, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70112, United States
  • GSK Investigational Site
    Durham, North Carolina 27705, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45229, United States
  • GSK Investigational Site
    Galveston, Texas 77555-0653, United States
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7580206, Chile
  • GSK Investigational Site
    Brits, 2000, South Africa
  • GSK Investigational Site
    George, 6529, South Africa
08

References and documents

Publications

  • Bradley J, Scholtz F, Brennan C, Zhao H, Weller S. Pharmacokinetics and safety of single-dose valacyclovir oral suspension in infants and children with current or potential herpesvirus infection. Poster presentation, 45th Annual Meeting Infectious Disease
  • Kimberlin DW, Jacobs RF, Weller S, van der Walt JS, Heitman CK, Man CY, Bradley JS. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age. Clin Infect Dis. 2010 Jan 15;50(2):221-8. doi: 10.1086/649212. PubMed 20014952 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2003 to primary completion in Feb 2007, 49 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2006
First posted
Feb 28, 2006
StartActual
Jan 25, 2003
Primary completionActual
Feb 28, 2007
CompletionActual
Feb 28, 2007
Last update
Sep 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00297206
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 28, 2006
Start date
Jan 25, 2003
Primary completion
Feb 28, 2007
Completion
Feb 28, 2007
Last update
Sep 11, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valacyclovir

Start the discussion